Ibruxen 140 MG (Ibrutinib)

Basic Product Information of Ibruxen (Ibrutinib) 140mg

How Ibruxen (Ibrutinib) Works

Ibruxen contains Ibrutinib, a first-in-class, potent, orally administered inhibitor of Bruton’s Tyrosine Kinase (BTK). BTK is a signalling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways, and plays a central role in the survival, proliferation, trafficking, and adhesion of malignant B cells in blood cancers such as CLL, MCL, WM, and MZL.

Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, irreversibly inhibiting its enzymatic activity. By blocking downstream B-cell receptor signalling, Ibruxen disrupts the survival and spread of malignant B cells, driving them towards programmed cell death (apoptosis) while also inhibiting cell migration and adhesion within the tumour microenvironment. In chronic GVHD, Ibrutinib is also thought to act partly through inhibition of a related kinase, ITK.

Because of this precise, mechanism-driven action, Ibruxen is classified as a targeted therapy rather than conventional chemotherapy. It is administered as a once-daily oral capsule, offering a convenient outpatient treatment option for patients with these blood cancers and cGVHD.

Indications for Ibruxen (Ibrutinib)

Ibruxen (Ibrutinib) is indicated for the following conditions:

Benefits of Ibruxen (Ibrutinib) 140mg

How to Take Ibruxen (Ibrutinib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Ibruxen treatment. Your haemato-oncologist will monitor complete blood counts monthly for cytopenias, assess for signs of bleeding or bruising, and monitor for cardiac arrhythmias such as palpitations, dizziness, or shortness of breath, with ECG evaluation where indicated. Monitoring also includes periodic blood pressure checks, renal function, given the risk of worsening kidney function during treatment, and vigilance for signs of infection and, in high tumour burden patients, tumour lysis syndrome. Treatment may be interrupted or dose-reduced to manage toxicity. Report any unusual bleeding, bruising, chest palpitations, breathlessness, or fever to your doctor immediately.

Drug Interactions and Important Information

Avoid concomitant use of Ibruxen with strong and moderate CYP3A inhibitors (such as ketoconazole, itraconazole, clarithromycin, and ritonavir) where possible, as these significantly increase Ibrutinib plasma exposure; if a moderate CYP3A inhibitor must be used, the dose should be reduced. Avoid concomitant use with strong CYP3A inducers (such as rifampicin, carbamazepine, and phenytoin), as these reduce Ibrutinib efficacy.

Use with caution alongside anticoagulants and antiplatelet agents (such as warfarin), as combined use may increase the risk of bleeding; supplements such as fish oil and vitamin E preparations should also be used cautiously. Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment. Ibruxen may have a minor effect on driving ability, so patients who feel dizzy or weak after taking a dose are advised not to drive. Women of childbearing potential should use effective contraception during treatment and for a period after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Ibruxen.

Side Effects and Precautions

Who Should Use Ibruxen (Ibrutinib)?

Ibruxen is suitable for adult patients diagnosed with Mantle Cell Lymphoma after at least one prior therapy, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma including 17p deletion, Waldenstrom’s Macroglobulinemia, Marginal Zone Lymphoma after prior anti-CD20-based therapy, or chronic Graft-Versus-Host Disease after failure of other systemic therapy. It is prescribed by haemato-oncologists and transplant specialists experienced in managing B-cell malignancies and post-transplant complications. A thorough medical assessment including cardiac evaluation, baseline blood counts, and renal and liver function is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Ibruxen under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Ibruxen is one of Everest’s specialty oncology products, offering an affordable and bioequivalent alternative to Imbruvica at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Ibruxen (Ibrutinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Ibruxen (Ibrutinib) from Mediaid Pharmacy?

Ibruxen represents a major advancement in the targeted treatment of B-cell blood cancers. As the generic equivalent of Imbruvica, it delivers the same active ingredient, Ibrutinib, with the same proven BTK-inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Ibruxen gives patients worldwide access to high-quality targeted therapy for CLL, MCL, WM, MZL, and cGVHD without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Ibrutinib option with worldwide delivery, Ibruxen from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Ibruxen (Ibrutinib)